2,6,16-KauranetriolCAS# 41530-90-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 41530-90-9 | SDF | Download SDF |
PubChem ID | 73554063 | Appearance | Powder |
Formula | C20H34O3 | M.Wt | 322.5 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (1S,4S,9R,10S,13R,14S)-5,5,9,14-tetramethyltetracyclo[11.2.1.01,10.04,9]hexadecane-3,7,14-triol | ||
SMILES | CC1(CC(CC2(C1C(CC34C2CCC(C3)C(C4)(C)O)O)C)O)C | ||
Standard InChIKey | MGTDZPRNONHJLG-QMVVIZBCSA-N | ||
Standard InChI | InChI=1S/C20H34O3/c1-17(2)8-13(21)9-18(3)15-6-5-12-7-20(15,11-19(12,4)23)10-14(22)16(17)18/h12-16,21-23H,5-11H2,1-4H3/t12-,13?,14?,15-,16+,18-,19+,20+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
2,6,16-Kauranetriol Dilution Calculator
2,6,16-Kauranetriol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1008 mL | 15.5039 mL | 31.0078 mL | 62.0155 mL | 77.5194 mL |
5 mM | 0.6202 mL | 3.1008 mL | 6.2016 mL | 12.4031 mL | 15.5039 mL |
10 mM | 0.3101 mL | 1.5504 mL | 3.1008 mL | 6.2016 mL | 7.7519 mL |
50 mM | 0.062 mL | 0.3101 mL | 0.6202 mL | 1.2403 mL | 1.5504 mL |
100 mM | 0.031 mL | 0.155 mL | 0.3101 mL | 0.6202 mL | 0.7752 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Koaburaside monomethyl ether
Catalog No.:BCN5471
CAS No.:41514-64-1
- Daturaolone
Catalog No.:BCN3904
CAS No.:41498-80-0
- 12-Oleanene-3,6-diol
Catalog No.:BCN3903
CAS No.:41498-79-7
- 3-Amino-1-phenyl-2-pyrazolin-5-one
Catalog No.:BCC8605
CAS No.:4149-06-8
- Belinostat (PXD101)
Catalog No.:BCC2153
CAS No.:414864-00-9
- Turkesterone
Catalog No.:BCN2363
CAS No.:41451-87-0
- Bruceantin
Catalog No.:BCN7618
CAS No.:41451-75-6
- Onetine
Catalog No.:BCN2102
CAS No.:41451-67-6
- Phalaenopsine Is
Catalog No.:BCN2016
CAS No.:41451-64-3
- (+)-N-Methylallosedridine
Catalog No.:BCN5470
CAS No.:41447-16-9
- (-)-N-Methylsedridine
Catalog No.:BCN5469
CAS No.:41447-15-8
- ODQ
Catalog No.:BCC6829
CAS No.:41443-28-1
- 1-(3,4-dimethoxyphenyl)-2-(4-allly-2,6-dimethoxyphenoxy)propan-1-ol
Catalog No.:BCN1445
CAS No.:41535-95-9
- N6-Cyclopentyladenosine
Catalog No.:BCC7160
CAS No.:41552-82-3
- SN-6
Catalog No.:BCC7273
CAS No.:415697-08-4
- RI-1
Catalog No.:BCC1896
CAS No.:415713-60-9
- Poricoic acid G
Catalog No.:BCN8267
CAS No.:415724-84-4
- Carboplatin
Catalog No.:BCC1170
CAS No.:41575-94-4
- 4,R-ajmalicine N-oxide
Catalog No.:BCN5473
CAS No.:41590-29-8
- (-)-Pinoresinol 4-O-glucoside
Catalog No.:BCN7251
CAS No.:41607-20-9
- Ylangenol
Catalog No.:BCN6705
CAS No.:41610-69-9
- Ciclopirox ethanolamine
Catalog No.:BCC4372
CAS No.:41621-49-2
- Lacinilene C
Catalog No.:BCN5474
CAS No.:41653-72-9
- Koaburaside
Catalog No.:BCN5475
CAS No.:41653-73-0
Efficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities.[Pubmed:29024590]
ACS Comb Sci. 2017 Dec 11;19(12):748-754.
A novel three-component, two-step, one-pot nucleophilic aromatic substitution (SNAr)-intramolecular cyclization-Suzuki coupling reaction was developed for the synthesis of benzo[h][1,6]naphthyridin-2(1H)-ones (Torins). On the basis of the new efficiently convergent synthetic route, a library of Torin analogs was synthesized. The antimalarial activities of these compounds were evaluated against asexual parasites using a growth inhibition assay and gametocytes using a viability assay.
Synthesis and Antimicrobial Evaluation of Fire Ant Venom Alkaloid Based 2-Methyl-6-alkyl-Delta(1,6)-piperideines.[Pubmed:29023124]
J Nat Prod. 2017 Oct 27;80(10):2795-2798.
The first synthesis of 2-methyl-6-pentadecyl-Delta(1,6)-piperideine (1), a major alkaloid of the piperideine chemotype in fire ant venoms, and its analogues, 2-methyl-6-tetradecyl-Delta(1,6)-piperideine (2) and 2-methyl-6-hexadecyl-Delta(1,6)-piperideine (3), was achieved by a facile synthetic method starting with glutaric acid (4) and urea (5). Compound 1 showed in vitro antifungal activity against Cryptococcus neoformans and Candida albicans with IC50 values of 6.6 and 12.4 mug/mL, respectively, and antibacterial activity against vancomycin-resistant Enterococcus faecium with an IC50 value of 19.4 mug/mL, while compounds 2 and 3 were less active against these pathogens. All three compounds strongly inhibited the parasites Leishmania donovani promastigotes and Trypanosoma brucei with IC50 values in the range of 5.0-6.7 and 2.7-4.0 mug/mL, respectively.
Social vulnerabilities as determinants of overweight in 2-, 4- and 6-year-old Spanish children.[Pubmed:29020368]
Eur J Public Health. 2018 Apr 1;28(2):289-295.
Background: Differences in obesity prevalence among vulnerable groups exist in childhood but it remains unclear whether these differences may be partly determined by socioeconomic status (SES), parental body mass index (BMI) and early life risk factors. We aimed to explore (i) longitudinal associations between belonging to a minority group and being overweight/obese at age 2, 4 and 6 and (ii) associations between accumulation of social vulnerabilities and being overweight/obese at age 6. Methods: In total, 1031 children (53.8% boys) were evaluated at birth and re-examined during a 6-year follow-up in a representative cohort of Aragon (Spain). Children from minority (vulnerable) groups included Spanish Roma/gypsies, Eastern Europeans, Latin Americans and Africans. Two more vulnerable groups were defined at baseline as children whose parents reported low occupation and education. Ethnicity, SES and parental BMI were collected via interviews. We used logistic mixed-effects models and adjusted for parental BMI, SES, mother's tobacco use, maternal weight gain, birth weight, infant weight gain and breastfeeding practices. Results: Regardless of confounders, Roma/gypsy children (OR = 4.63;[1.69-12.70]95%CI) and with Latin American background (OR = 3.04;[1.59-5.82]95%CI) were more likely to be overweight/obese at age 6 compared with non-gypsy Spanish group. Children with three vulnerabilities (OR = 2.18;[1.31-3.64]95%CI) were more likely to be overweight/obese at age 6 compared with children with no vulnerabilities. No associations were found between belonging to a minority group and overweight/obesity in children under 6. Conclusion: Interventions should target Roma/gypsy children, Latin American children and those who accumulate more vulnerabilities as they are at higher risk of being overweight/obese at age 6.
Characterization of immortalized human mammary epithelial cell line HMEC 2.6.[Pubmed:29022488]
Tumour Biol. 2017 Oct;39(10):1010428317724283.
Primary human mammary epithelial cells have a limited life span which makes it difficult to study them in vitro for most purposes. To overcome this problem, we have developed a cell line that was immortalized using defined genetic elements, and we have characterized this immortalized non-tumorigenic human mammary epithelial cell line to establish it as a potential model system. human mammary epithelial cells were obtained from a healthy individual undergoing reduction mammoplasty at SIU School of Medicine. The cells were transduced with CDK4R24C followed by transduction with human telomerase reverse transcriptase. Post all manipulation, the cells displayed a normal cell cycle phase distribution and were near diploid in nature, which was confirmed by flow cytometry and karyotyping. In vitro studies showed that the cells were anchorage dependent and were non-invasive in nature. The cell line expressed basal epithelial markers such as cytokeratin 7, CD10, and p63 and was negative for the expression of estrogen receptor and progesterone receptor. Upon G-band karyotyping, the cell line displayed the presence of a few cytogenic abnormalities, including trisomy 20 and trisomy 7, which are also commonly present in other immortalized mammary cell lines. Furthermore, the benign nature of these cells was confirmed by multiple in vitro and in vivo experiments. Therefore, we think that this cell line could serve as a good model to understand the molecular mechanisms involved in the development and progression of breast cancer and to also assess the effect of novel therapeutics on human mammary epithelial cells.